A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

NCT ID: NCT06994195

Last Updated: 2025-08-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 384 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-04
• Study Completion Date: 2027-12-31

Brief Summary

This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.

Conditions

Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BL-B01D1

Participants receive BL-B01D1 in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

BL-B01D1

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks.

Investigator's choice of chemotherapy

Participants receive Liposomal doxorubicin, Paclitaxel or Topotecan in the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: ACTIVE_COMPARATOR

Liposomal doxorubicin, Paclitaxel or Topotecan

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 4 weeks.

Interventions

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

Intervention Type: DRUG

Liposomal doxorubicin, Paclitaxel or Topotecan

Administration by intravenous infusion for a cycle of 4 weeks.

Intervention Type: DRUG

Other Intervention Names

iza-bren; izalontamab brengitecan; BMS-986507

Eligibility Criteria

Inclusion Criteria

1. Voluntarily sign the informed consent form and comply with the protocol requirements;

2. Age: ≥18 years old;

3. Expected survival time ≥3 months;

4. Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer;

5. Previously treated with a platinum-based regimen and confirmed to have platinum-resistant recurrence;

6. Previously received 1-3 lines of systemic anti-tumor therapy, with radiographic evidence of disease progression during or after the last line of treatment or intolerance to the current treatment prior to randomization;

7. For subjects with documented folate receptor-alpha (FRα) positivity, progression must have occurred after treatment with mirvetuximab soravtansine;

8. Agree to provide archived tumor tissue specimens or fresh tissue samples from the primary or metastatic lesions within the past 3 years;

9. Must have at least one measurable lesion as defined by RECIST v1.1;

10. ECOG performance status score of 0 or 1;

11. Toxicity from prior anti-tumor therapy has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;

12. No severe cardiac dysfunction, with left ventricular ejection fraction ≥50%;

13. Organ function levels must meet the requirements;

14. Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5×ULN;

15. For premenopausal women with childbearing potential, a serum pregnancy test must be performed within 7 days before starting treatment, and the result must be negative; they must not be breastfeeding. All enrolled patients should use adequate barrier contraception throughout the treatment period and for 6 months after treatment ends.

Exclusion Criteria

1. Use of chemotherapy, targeted therapy, biologic therapy, etc., within 4 weeks or 5 half-lives prior to study randomization and palliative radiotherapy, etc., within 2 weeks;

2. Patients with locally advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer who are eligible for radical locoregional therapy;

3. Front line received ADCs targeting topoisomerase I inhibitors or EGFR and/or HER3;

4. History of severe heart disease and cerebrovascular disease;

5. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;

6. Prolonged QT interval, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;

7. Diagnosed with active malignancy within 3 years before randomization;

8. Hypertension poorly controlled by two antihypertensive drugs;

9. Patients with poor glycemic control;

10. Patients with grade ≥1 radiation pneumonitis according to the RTOG/EORTC definition; Previous history of ILD;

11. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;

12. Patients with active central nervous system metastases;

13. Severe infection occurred within 4 weeks before randomization in study 13; Evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;

14. Patients with massive or symptomatic effusions or poorly controlled effusions;

15. Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;

16. Serious unhealed wound, ulcer or fracture within 4 weeks before signing the informed consent;

17. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;

18. Patients with inflammatory bowel disease, extensive bowel resection, immune enteritis, intestinal obstruction or chronic diarrhea;

19. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;

20. Had a history of autologous or allogeneic stem cell transplantation;

21. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;

22. A history of severe neurological or psychiatric illness;

23. Received other unmarketed investigational drugs or treatments within 4 weeks before randomization;

24. Subjects who were scheduled to be vaccinated or received live vaccine within 28 days before study randomization;

25. Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Sa Xiao, PHD

Role: CONTACT

xiaosa@baili-pharm.com

15013238943

Facility Contacts

Xiaohua Wu

Role: primary

Other Identifiers

BL-B01D1-310

Identifier Type: -

Identifier Source: org_study_id